ILB 3101
Alternative Names: ILB-3101Latest Information Update: 18 Nov 2024
Price :
$50 *
At a glance
- Originator Innolake Biopharm
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Oct 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06426680)
- 24 May 2024 Innolake Biopharm plans phase-I/II trial for Solid tumours (Late-stage disease, In Adults, In the elderly, Metastatic disease, Second-line therapy or greater) in August 2024 (IV) (NCT06426680),
- 05 Apr 2024 Pharmacodynamics, safety and pharmacokinetics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)